Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251

Gaetano Santulli^{1

2

3}, Salvatore Frullone⁴, Maria Morgante⁴, Gaetano Macina⁴, Antonella Pansini⁴, Jessica Gambardella^{1

3}, Angela Lombardi¹, Pasquale Mone^{1

2

5}

Affiliations

¹ Department of Medicine, Einstein-Sinai Diabetes Research Center (FIDAM), The Fleischer Institute for Diabetes and Metabolism (ES-DRC), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY.
² Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY.
³ International Translational Research and Medical Education Consortium (ITME), "Federico II" University, Naples, Italy.
⁴ Azienda Sanitaria Locale Avellino, Avellino, Italy.
⁵ Department of Preventive Medicine, Campania University, Naples, Italy.

Comment

Gaetano Santulli et al. Diabetes Care. 2022.

. 2022 Oct 1;45(10):e151-e152.

doi: 10.2337/dci22-0025.

Gaetano Santulli^{1

2

3}, Salvatore Frullone⁴, Maria Morgante⁴, Gaetano Macina⁴, Antonella Pansini⁴, Jessica Gambardella^{1

3}, Angela Lombardi¹, Pasquale Mone^{1

2

5}

¹ Department of Medicine, Einstein-Sinai Diabetes Research Center (FIDAM), The Fleischer Institute for Diabetes and Metabolism (ES-DRC), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY.
² Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY.
³ International Translational Research and Medical Education Consortium (ITME), "Federico II" University, Naples, Italy.
⁴ Azienda Sanitaria Locale Avellino, Avellino, Italy.
⁵ Department of Preventive Medicine, Campania University, Naples, Italy.

No abstract available

Comment on

Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G. Mone P, et al. Diabetes Care. 2022 May 1;45(5):1247-1251. doi: 10.2337/dc21-2434. Diabetes Care. 2022. PMID: 35287171 Free PMC article.
Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251.
Liang B, Gu N. Liang B, et al. Diabetes Care. 2022 Oct 1;45(10):e150. doi: 10.2337/dc22-0778. Diabetes Care. 2022. PMID: 36150058 No abstract available.

1. Liang B, Gu N. Comment on Mone et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 2022;45:1247–1251 (Letter). Diabetes Care 2022;45:e150. DOI: 10.2337/dc22-0778 - PubMed
1. Mone P, Lombardi A, Gambardella J, et al. . Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 2022;45:1247–1251 - PMC - PubMed
1. Mone P, Varzideh F, Jankauskas SS, et al. . SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension 2022;79:1663–1643 - PMC - PubMed
1. Mone P, Lombardi A, Kansakar U, et al. . Empagliflozin improves the microRNA signature of endothelial dysfunction in patients with HFpEF and diabetes. J Pharmacol Exp Ther 2022 - PMC - PubMed
1. Varzideh F, Kansakar U, Santulli G. SGLT2 inhibitors in cardiovascular medicine. Eur Heart J Cardiovasc Pharmacother 2021;7:e67–e68 - PMC - PubMed